[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"3H Pharmaceuticals Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100620214",false,"NCT07354711","A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","A Phase I\u002FII Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors","Inclusion Criteria:\n\n* Subjects must be willing and able to sign the ICF and to adhere to the study visit schedule and other protocol requirements.\n* Male or female subjects aged ≥18 years at the time of signing the ICF.\n* According to RECIST v1.1, there is at least one measurable lesion.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 point.\n* Life expectancy of ≥3 months.\n\nExclusion Criteria:\n\n* Meningeal diseases or carcinomatous meningitis.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage every two weeks or more frequently.\n* Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.\n* Any AEs induced by prior anti-tumor therapy having not resolved to Grade 1 or lower (except for alopecia or any other Grade 2 AEs assessed by the investigator as not being associated with any safety risk).\n* Any corneal or retinal disease\u002Fkeratopathy assessed by the investigator as of clinical significance, including but not limited to bullous\u002Fband keratopathy, corneal abrasion, inflammation\u002Fulceration, and keratoconjunctivitis.","ALL","18 Years",{"count":18,"type":19},170,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .",[26,27],"Lung Cancer","Stomach Cancer","RECRUITING","2026-01-18",{"date":31,"type":32},"2026-01-21","ACTUAL",{"date":34,"type":32},"2026-01-04",{"date":36,"type":19},"2029-01",{"name":38,"class":39},"3H Pharmaceuticals Co., Ltd.","INDUSTRY",""]